A Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent Pericarditis
Latest Information Update: 13 Jun 2025
At a glance
- Drugs KPL 387 (Primary)
- Indications Pericarditis
- Focus Registrational; Therapeutic Use
- Sponsors Kiniksa Pharmaceuticals
Most Recent Events
- 08 Jun 2025 Status changed from planning to not yet recruiting.
- 05 Jun 2025 According to a Kiniksa Pharmaceuticals media release, trial design is supported by data from the Phase 1 first-in-human single ascending dose study.
- 07 Mar 2025 New trial record